Literature DB >> 26244271

Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells.

Helga Helseth Hektoen1,2,3, Anne Hansen Ree1,3, Kathrine Røe Redalen3, Kjersti Flatmark1,2,4.   

Abstract

Carbonic anhydrase IX (CAIX) is a pivotal pH regulator under hypoxia, which by its tumor-specific expression represents an attractive target for cancer therapy. Here, we report on effects of the sulfamate CAIX inhibitor S4 (4-(3'-(3″,5″-dimethylphenyl)ureido)phenyl sulfamate) in colorectal carcinoma cell lines. S4 was administered under experimental hypoxia or normoxia to HT29, KM20L2 and HCT116 cells. Effects on survival, proliferation, pH, lactate extrusion and CAIX protein expression were evaluated. S4 treatment resulted in attenuated hypoxia-induced extracellular acidification and reduced clonogenic survival under hypoxia in HT29 cells. The pH effects were present only in a [Formula: see text]-free buffer system and were accompanied by decreased lactate extrusion. The main finding of this work was that S4 treatment caused alterations in CAIX ectodomain shedding. This merits further investigation to understand how sulfamates influence CAIX activity and how such drugs may be of use in cancer treatment.

Entities:  

Keywords:  Carbonic anhydrase IX; colorectal cancer; ectodomain shedding; extracellular pH; hypoxia; intracellular pH; sulfamate inhibitor

Mesh:

Substances:

Year:  2015        PMID: 26244271     DOI: 10.3109/14756366.2015.1069286

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  4 in total

Review 1.  Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies.

Authors:  Mateusz Kciuk; Adrianna Gielecińska; Somdutt Mujwar; Mariusz Mojzych; Beata Marciniak; Rafał Drozda; Renata Kontek
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

2.  Carbonic anhydrase 9 confers resistance to ferroptosis/apoptosis in malignant mesothelioma under hypoxia.

Authors:  Zan Li; Li Jiang; Shan Hwu Chew; Tasuku Hirayama; Yoshitaka Sekido; Shinya Toyokuni
Journal:  Redox Biol       Date:  2019-08-10       Impact factor: 11.799

Review 3.  Preclinical Evaluation of Ureidosulfamate Carbonic Anhydrase IX/XII Inhibitors in the Treatment of Cancers.

Authors:  Kaye J Williams; Roben G Gieling
Journal:  Int J Mol Sci       Date:  2019-12-02       Impact factor: 5.923

4.  The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy.

Authors:  Simon J A van Kuijk; Roben G Gieling; Raymon Niemans; Natasja G Lieuwes; Rianne Biemans; Brian A Telfer; Guido R M M Haenen; Ala Yaromina; Philippe Lambin; Ludwig J Dubois; Kaye J Williams
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.